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CONTAINING SEEDS AND SHELLS COMPARED WITH GLUCOSAMINE
SULFATE IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE -
A BLINDED, PARALLEL, RANDOMIZED STUDY
A. Petcharat, K. Wongsuphasawat. Mae Fah Luang Univ., Bangkok,
Thailand
Purpose: Knee osteoarthritis is a degenerative disease caused by
imbalance between formation and the destruction of cartilage, having
pain, and crepitating knee as the most prominent symptoms. Rose-hip
powder (RHP) is a well-known herbal remedy in Northern Europe, and
glucosamine sulfate (GS) is commonly used to relieve symptoms of
knee osteoarthritis. The purpose of this study was to compare the
efﬁcacy of a standardized Rose-hip powder, manufactured by Hyben-
Vital, Langeland, Denmark, to glucosamine sulfate, in a blinded, parallel,
randomized, controlled study.
Methods: Patients with moderate to severe symptoms of knee osteo-
arthritis according to the criteria of the American College of Rheuma-
tology, without infectious arthritis, and not taking either of the studied
supplements for the last 6 weeks before entering the study, were
randomly recruited. Primary endpoints were to measure the efﬁcacy of
each remedy, and to compare the efﬁcacy of the two remedies, in the
reduction of symptoms from knee osteoarthritis such as pain, stiffness
and functional disability, measured by WOMAC score, at the end of 3rd,
5th and 8th week of treatment. The Secondary endpoints included the
reduction of analgesic consumption and the incidence of adverse
reactions at the end of the 8th week of treatment. Statistical evaluation:
WOMAC score changes within group were analyzed by Repeated
Measure two-ways ANOVA. Subanalysis of values between groups was
done by t-test. Data are given as mean values  SD. P value of less than
0.050 is regarded as statistical signiﬁcant.
Results: A number of 46 patients, 24 patients, 3 males 21 females, mean
age of 58.2510.76 years, mean weight of 62.208.85, with mean
WOMAC total score of 44.1711.87, were included in the GS group and
22 patients, 1male, 21 female, mean age of 60.4110.00, meanweight of
61.9910.56, with mean WOMAC total score of 44.5113.17, were
included in the RHP group. All completed the study. There was no
signiﬁcant difference in the subject characteristics between groups at
the initial level. Glucosamine sulfate (GS) was given at the dose of 1500
mg per day, while Rose-hip powder (RHP) was given at 4500 mg per
day. Results showed that, total WOMAC scores at the end of 3rd, 5th and
8th week in GS group declined with statistically signiﬁcance from
44.1711.87 to 33.9210.88 (p<0.001), 24.8312.16 (p<0.001), and
17.4612.11 (p<0.001), respectively, while the RHP group also showed
statistically signiﬁcant decrease in total WOMAC score from
44.5013.17 to 29.5915.86 (p<0.001), 19.3614.87 (p<0.001) and
9.5413.59 (p<0.001) respectively. The total WOMAC scores of RHP
group was signiﬁcantly lower than GS group at the end of the 8th week
(p<0.044). WOMAC scores on pain and stiffness also decreased signif-
icantly in both groups, without statistical signiﬁcant difference between
groups. The RHP group showed lower WOMAC score on functional
disability, with statistical signiﬁcance (P<0.015) when compared to GS
group at the end of the 8th week. Both groups were able to reduce the
use of analgesics at the end of 8th week, with no signiﬁcant difference
between groups. The GS group demonstrated more incidences of
adverse reactions (27 incidences, 15 cases) than the RHP group (16
incidences, 10 cases).
Conclusions: In conclusion, both GS and RHP were able to signiﬁcantly
reduce symptoms of knee osteoarthritis, such as pain and stiffness, after
3weeks of treatment. RHP showed better efﬁcacy than GS in term of total
WOMAC score reduction, and functional disability reduction at the end of
the 8th week, with less evidence and severity of adverse reactions.407
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Purpose: Osteoarthritis (OA) is a multidimensional disease that affects
all anatomical joint structures, particularly cartilage, synovium andsubchondral bone. In turn, osteoporosis (OP) is a skeletal disorder
characterized by a compromised bone strength which substantially
increases the risk of fracture. Both are common disorders which affect
quality of life in the elderly. Despite this, there is not any drug at the
moment approved for the simultaneous prevention and treatment of
osteoporosis and osteoarthritis.
The aim of this study was to investigate the effect of a new formulation
in a combined rat model of OP and OA. The formulation (BIS076)
contains Vitamin D3, Hydroxyapatite as a source of calcium and
a natural extract from porcine cartilage. The latter is rich in bioactive
substances due to the mild conditions used in the manufacturing
process.
Methods: OP was induced by ovariectomy in female Wistar rats (180-
200g body weight, n¼ 15 rats/group) (week 0) and 2 weeks after (week
2) OA was induced by Anterior Cruciate Ligament Transection (ACLT).
All surgical procedures were carried out under deep anaesthesia with
isoﬂuorane (1.5 minimum alveolar concentration) which was followed
by the subcutaneous injection of butorphanol (2mg/kg). Animals were
maintained at a temperature of 212oC, with a 12 hour light/dark cycle
and with free access to food and tap water. BIS076 was administered
daily (oral gavage) at two doses from week 0 until week 12 after
ovariectomy. The low dose was 163.5 mg/kg/day and the high dose 245
mg/kg/day which correspond approximately to 1400 mg/day and 2100
mg/day in humans. A Control Group and an ovariectomized + ACLT
Group (Vehicle Group) were also included. After week 12, animals were
sacriﬁced. For the assessment of OA, histology was performed and
cartilage degeneration was evaluated by means of the OARSI score.
Synovitis degree was estimated according to the score proposed by
Krenn et al. Bone microarchitecture and density were assessed by
microCT.
Results: The preparation BIS076 has been shown to induce, at the 2
doses tested, a signiﬁcant reduction (approximately 50%) of the carti-
lage degradation according to the OARSI score. Synovial inﬂammation
was strongly reduced as well. In addition, microCT revealed that BIS076
treatment exerted a positive effect in bone structure, especially at the
high dose: Signiﬁcant increase in bone volume (p<0.05), bone surface
density (p<0.01), trabecular number (p<0.01) and signiﬁcant reduction
in the trabecular bone pattern factor (p<0.01) compared to the Vehicle
Group.
Conclusions: Our data demonstrate that treatment with BIS076 could
be an effective strategy to control the progression of experimental
Osteoarthritis and Osteoporosis. This approach holds promise for the
development of improved therapies targeting these chronic and
disabling diseases.408
THE ANTI-INFLAMMATORY CAPACITY OF ROSE-HIP IS STRONGLY
DEPENDENT ON THE SEEDS - A COMPARISON OF ANIMAL AND
HUMAN STUDIES
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Purpose: A standardized preparation from selected subspecies of rose-
hip, developed and produced on Langeland, Denmark, trade name
Hyben-Vital, has drawn increasing attention as an anti-inﬂammatory
agent and a meta-analysis indicate that the remedy can alleviate
symptoms of osteoarthritis. The powder consists of an equal amount of
shells and seeds. The purpose of this study was to evaluate if the anti-
inﬂammatory capacity is dependent on seeds.
Methods: The clinical studies were double-blinded, placebo-controlled
and randomized and lasted from 3 to 6 month. Blood samples for
laboratory analysis were drawn initially and after at least 3 month
treatment. As the in vivo inﬂammatory marker, C-reactive protein (CRP)
is not well established in animal models we used, chemotaxis, a modi-
ﬁed Boyden chamber technique, to measure migration of poly-
morphnucleated cells (PMN`s) to the inﬂammatory sites. Inhibition of
migration indicates anti-inﬂammatory property. The methodology is
well established and results in comparable data when testing different
animal species including horses and dogs. In studies on humans we
measured CRP, using normal laboratory routine, at the initial level and
again after 3 to 6 month of treatment. In the animal study, two different
preparations of Rose-hip powder were used: One version of powder
